Author
Jonathan Hadgraft
Other affiliations: University of London, University of Strathclyde, University of Wales ...read more
Bio: Jonathan Hadgraft is an academic researcher from University College London. The author has contributed to research in topics: Transdermal & Stratum corneum. The author has an hindex of 66, co-authored 349 publications receiving 15661 citations. Previous affiliations of Jonathan Hadgraft include University of London & University of Strathclyde.
Topics: Transdermal, Stratum corneum, Permeation, Membrane, Azone
Papers published on a yearly basis
Papers
More filters
TL;DR: The strong association between both genetic barrier defects and environmental insults to the barrier with AD suggests that epidermal barrier dysfunction is a primary event in the development of this disease.
694 citations
Book•
17 Apr 2007
TL;DR: Modified-release drug delivery technology, Modified-release drugs delivery technology , and modified-release delivery technology are used in medicine and medical equipment.
Abstract: Modified-release drug delivery technology , Modified-release drug delivery technology , کتابخانه مرکزی دانشگاه علوم پزشکی تهران
454 citations
TL;DR: The mechanism of nucleation retardation by the polymers is explained in terms of association of HA with the polymer through hydrogen bonding, the extent of which is dependent on the hydrogen bonding functional groups that are exposed at each face of the crystal.
391 citations
TL;DR: An overview of various modeling approaches of skin permeability with respect to their advantages, limitations and future prospects is provided.
303 citations
293 citations
Cited by
More filters
TL;DR: Third-generation delivery systems target their effects to skin's barrier layer of stratum corneum using microneedles, thermal ablation, microdermabrasion, electroporation and cavitational ultrasound for delivery of macromolecules and vaccines.
Abstract: Transdermal drug delivery has made an important contribution to medical practice, but has yet to fully achieve its potential as an alternative to oral delivery and hypodermic injections. First-generation transdermal delivery systems have continued their steady increase in clinical use for delivery of small, lipophilic, low-dose drugs. Second-generation delivery systems using chemical enhancers, noncavitational ultrasound and iontophoresis have also resulted in clinical products; the ability of iontophoresis to control delivery rates in real time provides added functionality. Third-generation delivery systems target their effects to skin's barrier layer of stratum corneum using microneedles, thermal ablation, microdermabrasion, electroporation and cavitational ultrasound. Microneedles and thermal ablation are currently progressing through clinical trials for delivery of macromolecules and vaccines, such as insulin, parathyroid hormone and influenza vaccine. Using these novel second- and third-generation enhancement strategies, transdermal delivery is poised to significantly increase its impact on medicine.
2,595 citations
TL;DR: The present review outlines the major new findings on the pharmaceutical applications of chitosan-based micro/nanoparticulate drug delivery systems published over the past decade and discusses critically the usefulness of these systems in delivering the bioactive molecules.
2,314 citations
TL;DR: The chemical structure and relevant biological properties of chitosan for regenerative medicine have been summarized as well as the methods for the preparation of controlled drug release devices and their applications.
2,312 citations
2,057 citations
TL;DR: It is timely to summarize the polymeric systems that undergo sol-gel transitions, particularly due to temperature, with emphasis on the underlying transition mechanisms and potential delivery aspects.
2,048 citations